Constance H. Keyserling
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
Journal: Cardiovascular diagnosis and therapy
Published: June 02, 2017
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.
Journal: Clinical drug investigation
Published: February 19, 2017
HDL mimetic CER-001 targets atherosclerotic plaques in patients.
Journal: Atherosclerosis
Published: March 24, 2016
HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.
Journal: PloS one
Published: March 18, 2015
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.
Journal: Journal of lipid research
Published: January 07, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
Journal: American heart journal
Published: November 04, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
Journal: European heart journal
Published: May 01, 2014
CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Journal: Atherosclerosis
Published: July 02, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026